Constrained Peptide Drugs Market Size, Share & Trends Analysis Report by Peptide Type (Disulfide-Rich Peptides (DRPs) and Cyclic Peptides) and Potential Product (BT5528, Rusfertide (PTG-300), PN-943, PN-235, and Zilucoplan (RA101495)), Region And Segment Forecasts, 2025-2034

Global Constrained Peptide Drugs Market Size is valued at USD 1.5 Bn in 2024 and is predicted to reach USD 6.7 Bn by the year 2034 at an 16.3% CAGR during the forecast period for 2025-2034.

Polypeptide chains with cyclic rings make up cyclic peptides. The ring structure can be created by joining the ends of the peptide together with an amide bond or another chemically stable bond such as lactone, ether, thioether, disulfide, and so on. Many biologically active cyclic peptides are produced through the process known as N-to-C (or head-to-tail) cyclization, which involves the production of amide bonds between the amino and carboxyl termini.

In clinical settings, a number of cyclic peptides from nature are employed. A variety of factors, such as an increase in the number of older individuals, an increase in the prevalence of chronic diseases, and a rise in patient knowledge of peptide therapies breakthroughs, are projected to drive the development of the market for peptide therapeutics.

The increase in product development and technical advancements is another prominent market trend that is projected to boost expansion in the future years. At first, COVID-19 had a significant effect on market expansion. For instance, according to a Frontiers article from May 2022, the pandemic led to the development of many peptide-based vaccines and medication candidates, which had a favourable impact on the management of COVID-19 infections. As a result, the pandemic greatly influenced the market's expansion. The market, however, is anticipated to have steady development during the projected period now that the epidemic has passed. 

Competitive Landscape:

Some of the major key players in the Constrained Peptide Drugs Market are:

 • Aileron Therapeutics, Inc.
• Bicycle Therapeutics plc
• Spexis AG
• Protagonist Therapeutics Inc.
• Santhera Pharmaceuticals
• Union Chimique Belge S.A. (UCB)
• Creative Peptides
• Biosynth (Pepscan)
• Pepticom Ltd.
• PeptiDream Inc.
• Bio-Synthesis Inc
• CPC Scientific Inc.
• Circle Pharma
• Zealand Pharma
• Chugai Pharmaceutical Co. Ltd.

Market Segmentation:

The Constrained Peptide Drugs market is segmented on the basis of Peptide Type and Potential Product. By Peptide Type, the market is segmented into Disulfide-Rich Peptides (DRPs) and Cyclic Peptides. On the basis of Potential Products, the market is segmented into BT5528, Rusfertide (PTG-300), PN-943, PN-235, and Zilucoplan (RA101495).

Based On Peptide Type, The Disulfide-Rich Peptides (Drps) Segment Is Accounted As A Noteworthy Contributor In The Constrained Peptide Drugs Market

The pipeline-restricted peptides with either few or no licenced medications for the condition are included in the disulfide-rich peptides (DRPs) category, which is predicted to dominate the worldwide constrained peptide pharmaceuticals market. A group of peptides known as DRPs have many intramolecular disulfide bonds, which give them exceptional structural stability and bioactive characteristics. Due to their distinctive disulfide link configuration, these peptides are also known as cysteine-rich or cystine-knot peptides.

The Zilucoplan (RA101495) Segment Witnessed Growth At A Rapid Rate

The Zilucoplan (RA101495) segment is projected to grow rapidly in the global constrained peptide drugs market. UCB Pharmaceuticals is creating Zilucoplan to treat myasthenia gravis (MG) and other complement-mediated diseases. An autoimmune condition called myasthenia gravis damages the neuromuscular junction and results in tiredness and muscle weakening. Zilucoplan is made to block the complement system's C5 protein, which is involved in inflammation and the immunological response.

The North America Constrained Peptide Drugs Market Holds A Significant Revenue Share In The Region

Due to the growing need for anti-cancer medications, the rising incidence of cardiovascular disorders and other diseases, as well as the high demand for peptide and anticoagulant drugs, North America is anticipated to hold a sizable share of the global market for these medications throughout the forecast period. Aspects such as the rising burden of cancer and the rising frequency of cardiovascular diseases are expected to increase demand for peptide and anticoagulant medications.

Constrained Peptide Drugs Market Report Scope:

Segmentation of Constrained Peptide Drugs Market-

Constrained Peptide Drugs Market By Peptide Type-

• Disulfide-Rich Peptides (DRPs)
• Cyclic Peptides

Constrained Peptide Drugs Market By Potential Product-

• BT5528
• Rusfertide (PTG-300)
• PN-943
• PN-235
• Zilucoplan (RA101495)

Constrained Peptide Drugs Market By Region-

North America-

• The US
• Canada

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Mexico
• Argentina
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa
• Rest of Middle East and Africa